World Library  
Flag as Inappropriate
Email this Article

HT2c receptor agonist

Article Id: WHEBN0037051328
Reproduction Date:

Title: HT2c receptor agonist  
Author: World Heritage Encyclopedia
Language: English
Subject: Drug discovery
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

HT2c receptor agonist

Serotonin 5-HT2 receptors are stimulated by monoaminergic neurotransmitters including serotonin, dopamine and norepinephrine. 5-HT2 receptor stimulation cause a buildup of intracellular inositol triphosphate and thereby an increase of cytosolic Ca2+. 5-HT2C receptor agonists are attractive drug targets that have potential use in the treatment of a number of conditions including obesity, psychiatric disorders, sexual dysfunction and urinary incontinence.[1][2][3]

The 5-HT2C receptors are one of three subtypes that belong to the serotonin 5-HT2 receptor subfamily along with 5-HT2A and 5-HT2B receptors. The development of 5-HT2C agonists have been a major obstacle, because of severe side effects due to a lack of selectivity over 5-HT2A and 5-HT2B receptors. Activation of 5-HT2A receptors can induce hallucinations, and the activation of 5-HT2B receptors has been implicated in cardiac valvular insufficiency and possibly in pulmonary hypertension.[4][5]

Discovery

In the late 1960s, non-selective serotonin receptor antagonists demonstrated a relationship between serotonin receptors and food intake. Later on animal studies showed that serotonin receptor agonists might act as a mediator of satiety.[6] Serotonin has been implicated as a critical factor in the short term regulation of food intake and by promoting weight loss associated with hyperphagia.[7] The 5-HT2C receptor subtype was shown to be one of the principal mediators through which serotonin exert its anorectic effects in rodents by using pharmacological and genetic tools. Subsequently these receptors became a promising pharmacotherapeutic target for further investigation for the treatment of obesity.[8] The development of 5-HT2C receptor knock-out mice in the mid-1990s was a hallmark achievement in the identification and development of serotonergic drugs for weight loss. These knock-out mice were hyperphagic which led to obesity, partial leptin resistance, increased adipose deposition, insulin resistance and impaired glucose tolerance. Therefore the researchers found a functional role for the receptors in serotonergic regulation of food intake and body weight.[5][9] Later on research showed that 5-HT2C receptors have been proposed as a therapeutic target for the treatment of multiple central nervous system (CNS) disorders including; psychiatric disorders, obesity, sexual dysfunction and urinary incontinence.[7]

History

Fenfluramine (market names Pondimin, Ponderax and Adifax) was discovered in 1972 as it came out of the search for an anorectic compound lacking the effects of psycho-stimulants and sympathomimetic agents, such as amphetamines. At the time amphetamines were almost the only form of anorectic drugs available, however the side effects made them difficult to use. Fenfluramine increases serotonin levels and imparts a sensation of fullness, leading to a lower intake of food. Fenfluramine was sold as a racemic mix of two enantiomers, dexfenfluramine and levofenfluramine.[10][11]

In 1994, sales of the combination drug Fen-phen (fenfluramine and phentermine) increased dramatically, this combination produced substantial and apparent synergistic effect in promoting weight loss. After a while, reports regarding severe side effects associated with heart valve abnormalities and an increased risk of pulmonary hypertension came to light so products containing fenfluramine were removed from the U.S market, followed by other markets around the world.[12][13][14]

Dexfenfluramine inhibits serotonin re-uptake and stimulates the release of serotonin. In 1996, dexfenfluramine became the first drug approved in the U.S as a long-term anti-obesity drug. During clinical trials, observation of dexfenfluramine usage led to the conclusion that it could cause side effects such as dry mouth, diarrhea and drowsiness. In the mid-1990s the U.S. FDA then approved dexfenfluramine as a weight loss drug, however after several complaints about the drug cardiovascular effect it was banned in the U.S in 1997.[10][15][16]

It appears that the 5-HT2B receptors, expressed in cardiac valves are responsible for the valvulopathies reported from the use of fenfluramine and dexfenfluramine.[17]

The serotonin receptor agonist m-chlorophenylpiperazine (mCPP) has a significant affinity for 5-HT2C receptors. mCPP is not ideal because of multiple side effects due to non-selectivity over 5-HT2A and 5-HT2B receptors. The hypophagic effect of mCPP is absent in 5-HT2C receptor knock-out mice, suggesting that it is mediated via 5-HT2C receptor activation. Repeated administration of mCPP to humans might result in decreased food intake and weight loss. Nowadays mCPP is used as a prototype for drug discovery of selective 5-HT2C receptor agonists.[18][19][20]

Mechanism of action

Figure 1 – Mechanism of action. A hypothetical model for the agonist activation of 5-HT2C receptor. Activation leads to accumulation of inositol phosphates and increase in intracellular Ca2+. Receptor activation also stimulates the ERK pathway and RhoA/PLD pathway.

The 5-HT2C receptors are coupled to extracellular signal-regulated kinase (ERK) pathway which is activated by neurotrophins and other neuroactive chemicals. The production of these chemicals effects neuronal differentiation, survival, regeneration, and structural and functional plasticity. Early studies of the ERK pathway showed that mood stabilizers for the treatment of manic-depressive illness stimulated the pathway. This led to the understanding that stimulation of the 5-HT2C receptors could also initiate less manic-depressive conditions like mood stabilizers do.[21][22][23][3]

The 5-HT2C receptors are restricted to the CNS where they can be found in several locations, with the highest density in the choroid plexus. It can be found in other areas in the brain as well and typically those who are associated with regulation of food intake, including the nucleus of the solitary tract, dorsomedial hypothalamus, paraventricular hypothalamic nucleus and the amygdala. With the knowledge of their location, it might be possible to explain the effect they have in integral function in the control of many physiological and behavioral responses, such as feeding, anxiety, temperature regulation, locomotion, sexual behavior and the occurrence of seizures.[24][25]

Binding

The 5-HT2C receptors and ligand binding

Figure 2. A schematic representation of the two state-model in which the 5-HT2C receptor are in equilibrium between an active state (R*) and an inactive state (R).

5-HT2 receptors are seven-transmembrane (7TM) ligand-independent G protein-coupled receptors that have the capacity to regulate cellular signaling in the absence of a ligand. This can be explained by a two-state model (Figure 2) where the receptor is in equilibrium between two states, an active state (R*) and an inactive state (R). Basal effector activity is defined, in part, by the absolute level of (R*), which will increase along with increasing receptor density. Ligands that preferentially bind to and stabilize the R state are termed inverse agonists and reduce the effector activity. Agonists preferentially bind to and stabilize the R* state, thereby increasing effector activity. Neutral antagonists show equal affinity for both conformations and do not alter the equilibrium between the two states, however they occupy the receptor and can block the effect of both agonists and inverse agonists.[26][27]

5-HT2C and 5-HT2A receptors have a similar amino acid sequence homology, with ~50% overall sequence identity and ~80% within the TM domains. These two receptors share a high pharmacological profile given this similarity in sequence homology. Moreover, both these receptors couple the same cellular signal transduction pathways, PLC and PLA2, that lead to an accumulation of inositol phosphates and Ca2+ within the postsynaptic cell.[26]

The 5-HT2C receptors are the only 7TM receptors known to undergo a post-transcriptional process of RNA editing. The 5-HT2C receptor gene is found on the X-chromosome, Xq24. This gene product undergoes RNA editing process leading to a decrease in agonist binding affinity, however antagonist binding remains unaltered. This process of RNA editing generates 14 unique receptor isoforms of the 5-HT2C receptor that differ in three amino acids in the second intracellular loop.[26][28]

Serotonin binding to 5-HT2C

Serotonin is an endogenous non-selective agonist for the 5-HT2C receptor with a binding constant of Ki = 16.0 nM. When serotonin binds to the receptors, the most important contacts are in TM helixes 3, 5 and 6 (Figure 3), while the other four TM helixes do not interact directly with the serotonin compound. When binding of serotonin takes place, the protonated primary amine site forms a salt bridge with D134 residue in TM 3, as well as forming a hydrogen bond with residue S138 in TM 3. The aromatic indole ring forms a strong Van der Waals interaction with residues F223 in TM 5 and F328 in TM 6. The ring falls tight into the receptor pocket, stacked between two phenylalanines. Amine of the indole group forms a hydrogen bond with S219 residue in TM 5 and hydroxide substituent of the indole forms hydrogen bonds both with residue S131 in TM 3 and I332 in TM 6. There is also a strong Van der Waals interaction between the indole and I332 in TM 6.[29]

Figure 3. Outline of the 5-HT2C receptor. The most important contacts when serotonin binds are with residues in TM helixes 3, 5, and 6.

Pharmacophore

Figure 4. The best fit mapped with the four features of the pharmacophore.

In the drug discovery process of a 5-HT2C agonist a pharmacophore module has been used to discover novel 5-HT2C receptor ligands. The pharmacophore has four features; one aromatic ring, two hydrophobic features and one positive ionizable feature. Figure 4 shows an example of a compound that fits the agonist pharmacophore perfectly. The nitrogen atom of piperazine fits the positive ionizable feature, the benzofuran part fits the aromatic ring and one hydrophobic, and the trifluoromethane part fits another hydrophobic feature of the pharmacophore.[30]

Structure-activity relationships

A structure-activity relationship was determined from the best hits made from the pharmacophore model, described above. These hits contained a pyrazolo[3,4-d]pyrimidine core shown in figure 5, which is important for potency toward the 5-HT2C receptors, and to obtain maximum potency two substituents are linked to the core structure. The first substituent is a piperazine ring, containing a small hydrophobic group and the second substituent is a phenyl part containing a halogen and/or oxygen containing side chain (electronegative groups), see derivatives 1 and 2 in figure 5. Addition of aromatic groups to the piperazine ring reduces potency (derivative 4 in figure 5) and the absence of piperazine ring or substitution with other aliphatic- or cyclic groups reduces potency as well (derivatives 5 and 6 in figure 5).[30]

Pyrazolo[3,4-d]pyrimidine core
Derivative 1
Derivative 2
Derivative 3
Derivative 4
Derivative 5
Figure 5. Pyrazolo[3,4-d]pyrimidine derivatives.
Figure 6. Lorcaserin ((1R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine).
mCPP (meta-chlorophenylpiperazine)
Figure 7. mCPP and a potent derivative.

Series of 3-benzazepine derivatives, such as Lorcaserin (Figure 6) have been evaluated for their potency and selectivity for the 5-HT2C receptors. Lorcaserin is a very potent agonist but it is important for the potency to have a chloro substituent in position 8 of the compound. Moving the chlorine atom around the ring reduces the potency significantly.[31][5][32]

Compounds such as mCPP (Figure 7) containing arylpiperazine core show good potency toward the 5-HT2C receptors, though the main problem is that they do not have sufficient selectivity for the 5-HT2C receptors over the other two receptor subtypes. Many derivatives have been examined to increase the selectivity. Derivatives lacking the arylpiperazine core, such as 4-aryl-1,2,3,6-tetrahydropyridinum chlorine analogues, are more favorable for potency and selectivity over the other two receptors (Figure 7).[33]

Drug development

Obesity

Obesity is a global epidemic health problem and has received considerable attention as a major public hazard. Obesity is a chronic pathological and costly disease of abnormal or excessive fat accumulation in the body.[34]

Wealth of data indicates that 5-HT2C receptor activation will regulate appetite and food consumption, probably by promoting satiety. Given this appetite suppression by activation of 5-HT2C, selective agents with high affinity for this receptor over 5-HT2B and 5-HT22A are being developed for the treatment of obesity.[35][4]

As of this day, Lorcaserin is the only agent that has completed phase III in clinical trials, and has been approved by the U.S. Food and Drug Administration (FDA). Previous agents have all been removed from the U.S market.[4]

Lorcaserin

Lorcaserin is a full agonist for 5-HT2C and 5-HT2B receptors and partial agonist for 5-HT2A receptors (75% of the maximal response elicited by serotonin).[5] Lorcaserin is a potent and selective 5-HT2C agonist with rapid oral absorption that shows dose-dependent decrease in food intake and body weight. Lorcaserin affects body weight by producing a negative energy balance through reduced food intake (energy intake) without alterations in energy expenditure and substrate oxidation.[9] Lorcaserin has a high affinity for the 5-HT2C receptors, with 18-fold selectivity over 5-HT2A receptors and 104-fold over 5-HT2B receptors.[5] The predicted blood concentration to stimulate 2A and 2B receptors is approximately 1400-fold for 2B and 250-fold for 2A, above the blood concentration that is required to stimulate the 2C receptors. This functional selectivity is critical to prevent potential side effects and suggests that the theoretical risk of cardiac valvulopathy is very low. Clinical trials have supported this theory since they have not revealed any side effects on heart valves or pulmonary artery pressure like the former obesity drugs. Lorcaserin is well tolerated in general, but the most frequent adverse effect are headache, nausea and dizziness.[5][9]

Psychiatric disorders

Serotonin plays an important role in numerous physiological conditions. 5-HT2 receptor antagonists have long been known, but recently 5-HT2 receptor agonists are becoming promising agents in the development for new antipsychotic drugs. Most pharmacological researches on antipsychotic drugs have concentrated on the 5-HT2A receptor subtype, however recent studies show that agonist activity on 5-HT2A receptors can cause hallucination. Comparison of SSRIs and the 5-HT2C receptor agonists showed that the agonists decreased immobility time and increased swimming time in the FST (forced swim test) in rats in a manner comparable to SSRIs. In the 1990s 5-HT2C receptors have received more attention as many studies have shown that selective 5-HT2C receptor agonists may be more suited in the treatment for psychotic indications.[36][37]

A 5-HT2C agonist may be expected to reduce positive symptoms of schizophrenia by reducing dopamine release in the mesolimbic dopamine pathway. Vabicaserin (SCA-136) is a 5-HT2C agonist that has shown promise in preliminary testing for the treatment of schizophrenia.[38]

Vabicaserin

Vabicaserin has a high affinity for 5-HT2C receptors and has low affinity for 5-HT2B and 5-HT2A receptors. Vabicaserin is a full agonist with approximately 4-fold more selective for 5-HT2C, over these related receptors in terms of binding affinity. Vabicacserin is a full agonist in stimulating the 5-HT2C receptor, it was discovered when a class of tetrahydroquinoline-fused diazepines were being researched for possible potent 5-HT2C receptor agonists.[39]

As of 2012 Vabicaserin is in clinical trials for the treatment of schizophrenia. Long-term administration of Vabicaserin significantly decreases the number of spontaneously active mesocorticolimbic dopamine neurons without affecting nigrostriatal dopamine neurons, consistent with effects of atypical antipsychotic agents. The outcome of clinical studies for Vabicaserin may reveal whether 5-HT2C receptors can be possible targets for the treatment of schizophrenia.[40]

Sexual dysfunction

Activation of 5-HT2C receptor subtype has been reported to mediate numerous effects, such as penile erection.[41][42] Based on multiple studies, results show that several 5-HT2C receptor agonists, including mCPP and YM348 induce penile erections in rats,[43] but mCPP seems to mimic both vasodilation and vasoconstriction. The vasodilator action is mediated by 5- HT1D receptors, whereas the vasoconstriction effect involves 5-HT2 receptor activation.[44] YM-348 is a highly selective 5-HT2C agonist and results show that YM348 can induce penile erections and hypolocomotion (induced at a high dose) in rats, as did other 5-HT2C receptor agonists. These effects were completely inhibited by a selective 5-HT2C receptor antagonist, SB-242,084. Therefor results suggest that YM348 is a potent and orally active 5-HT2C receptor agonist.[45][46]

Urinary incontinence

Serotonin has been found to play a key role in mechanisms involved in micturition and continence. Many potent compounds with high selectivity for 5-HT2C receptors have been synthesized and are promising candidates for further development for the treatment of stress urinary incontinence (SUI).[46]

Current status

Many exogenous agents have been developed since the discovery of 5-HT2C receptors. Thus far a small number of agonists, with sufficient selectivity for the 5-HT2C receptors over the other subtypes have been studied in clinic. A variety of other 5-HT2C receptor agonists remain in pre-clinical developments, like Ro60-0175, WAY-163,909 and the inverse agonist SB-243,213. Evidence supports a therapeutic potential of 5-HT2C receptor modulation in the treatment of a variety of pathological conditions, including schizophrenia, obesity, urinary incontinence and sexual dysfunction.[38]

Compound name Chemical name Mode of action Company Phase of development Indication Reference
PRX-00933 N/A 5-HT2C agonist Proximager Phase III (2011) Obesity and diabetes [47]
Vabicaserin (9aR,12aS)-4,5,6,7,9,9a,10,11,12,12a- decahydrocyclopenta[c][1,4]diazepino[6,7, 1-ij]quinoline 5-HT2C agonist Pfizer Phase I (February, 28th,2012) Schizophrenia [48]
Lorcaserin 1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl- 1H-3-benzazepine 5-HT2C agonist Arena Pharmaceuticals FDA approved (June 27, 2012) Obesity [49]

See also

References

  1. ^ Wacker, DA; Miller, KJ (2008). "Agonists of the serotonin 5-HT2C receptor: Preclinical and clinical progression in multiple diseases". Current Opinion in Drug Discovery & Development 11 (4): 438–45.  
  2. ^ Cryan, John F.; Lucki, Irwin (2000). Receptors"2C"Antidepressant-Like Behavioral Effects Mediated by 5-Hydroxytryptamine. The Journal of Pharmacology and Experimental Therapeutics 295 (3): 1120–6.  
  3. ^ a b Tsui, Marco M.; York, John D. (2010). "Roles of inositol phosphates and inositol pyrophosphates in development, cell signaling and nuclear processes". Advances in Enzyme Regulation 50 (1): 324–37.  
  4. ^ a b c Wang, Yu; Bai, Y (2010). "The use of lorcaserin in the management of obesity: A critical appraisal". Drug Design, Development and Therapy 5: 1–7.  
  5. ^ a b c d e f Thomsen, W. J.; Grottick, A. J.; Menzaghi, F.; Reyes-Saldana, H.; Espitia, S.; Yuskin, D.; Whelan, K.; Martin, M.; Morgan, M.; Chen, W.; Al-Shamma, H.; Smith, B.; Chalmers, D.; Behan, D. (2008). "Lorcaserin, a Novel Selective Human 5-Hydroxytryptamine2C Agonist: in Vitro and in Vivo Pharmacological Characterization". Journal of Pharmacology and Experimental Therapeutics 325 (2): 577–587.  
  6. ^ Bickerdike, Mike J.; Vickers, Steven P.; Dourish, Colin T. (1999). "5-HT2C receptor modulation and the treatment of obesity". Diabetes, Obesity and Metabolism 1 (4): 207–14.  
  7. ^ a b Liu, K. K. -C.; Lefker, B. A.; Dombroski, M. A.; Chiang, P.; Cornelius, P.; Patterson, T. A.; Zeng, Y.; Santucci, S.; Tomlinson, E.; Gibbons, C. P.; Marala, R.; Brown, J. A.; Kong, J. X.; Lee, E.; Werner, W.; Wenzel, Z.; Giragossian, C.; Chen, H.; Coffey, S. B. (2010). "Orally active and brain permeable proline amides as highly selective 5HT2c agonists for the treatment of obesity". Bioorganic & Medicinal Chemistry Letters 20 (7): 2365.  
  8. ^ Garfield, A. S.; Heisler, L. K. (2008). "Pharmacological targeting of the serotonergic system for the treatment of obesity".  
  9. ^ a b c Martin, Corby K.; Redman, Leanne M.; Zhang, Jinkun; Sanchez, Matilde; Anderson, Christen M.; Smith, Steven R.; Ravussin, Eric (2010). "Lorcaserin, A 5-HT2C Receptor Agonist, Reduces Body Weight by Decreasing Energy Intake without Influencing Energy Expenditure".  
  10. ^ a b Devereux, Richard B. (1998). "Appetite Suppressants and Valvular Heart Disease". New England Journal of Medicine 339 (11): 765–6.  
  11. ^ Thomas, SH; Butt, AY; Corris, PA; Egan, JJ; Higenbottam, TW; Madden, BP; Waller, PC (1995). "Appetite suppressants and primary pulmonary hypertension in the United Kingdom".  
  12. ^ Smith, Brian M; Thomsen, William J; Grottick, Andrew J (2006). "The potential use of selective 5-HT2C agonists in treating obesity". Expert Opinion on Investigational Drugs 15 (3): 257–66.  
  13. ^ Staten, M A (2007). "Challenges in the Discovery and Development of New Agents for the Treatment of Obesity". Clinical Pharmacology & Therapeutics 81 (5): 753–5.  
  14. ^ Greenway, Frank L.; Bray, George A. (2010). "Combination Drugs for Treating Obesity". Current Diabetes Reports 10 (2): 108–15.  
  15. ^ Toornvliet, AC; Pijl, H; Hopman, E; Elte-De Wever, BM; Meinders, AE (1996). "Serotoninergic drug-induced weight loss in carbohydrate craving obese patients". International journal of obesity and related metabolic disorders 20 (10): 917–20.  
  16. ^ Weissman, Neil J.; Panza, Julio A.; Tighe, John F.; Gwynne, John T. (2001). "Natural History of Valvular Regurgitation 1 Year after Discontinuation of Dexfenfluramine Therapy: A Randomized, Double-Blind, Placebo-Controlled Trial".  
  17. ^ Fitzgerald, L. W.; Burn, T. C.; Brown, B. S.; Patterson, J. P.; Corjay, M. H.; Valentine, P. A.; Sun, J. H.; Link, J. R.; Abbaszade, I.; Hollis, J. M.; Largent, B. L.; Hartig, P. R.; Hollis, G. F.; Meunier, P. C.; Robichaud, A. J.; Robertson, D. W. (2000). "Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine". Molecular pharmacology 57 (1): 75–81.  
  18. ^ Tecott, Laurence H.; Sun, Linda M.; Akana, Susan F.; Strack, Alison M.; Lowenstein, Daniel H.; Dallman, Mary F.; Julius, David (1995). "Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors". Nature 374 (6522): 542–6.  
  19. ^ Hoyer, Daniel (1988). "Functional Correlates of Serotonin 5-HT1 Recognition Sites".  
  20. ^ Sargent, P. A.; Sharpley, A. L.; Williams, C.; Goodall, E. M.; Cowen, P. J. (1997). "5-HT2C receptor activation decreases appetite and body weight in obese subjects".  
  21. ^ Labasque, Marilyne; Meffre, Julie; Carrat, Gaelle; Becamel, Carine; Bockaert, Joël; Marin, Philippe (2010). "Constitutive Activity of Serotonin2C Receptors at G Protein-Independent Signaling: Modulation by RNA Editing and Antidepressants". Molecular Pharmacology 78 (5): 818–26.  
  22. ^ Van Oekelen, Dirk; Luyten, Walter H.M.L; Leysen, Josée E (2003). "5-HT2A and 5-HT2C receptors and their atypical regulation properties". Life Sciences 72 (22): 2429–49.  
  23. ^ Su, Wenjuan; Chardin, Pierre; Yamazaki, Masakazu; Kanaho, Yasunori; Du, Guangwei (2006). "RhoA-mediated Phospholipase D1 signaling is not required for the formation of stress fibers and focal adhesions". Cellular Signalling 18 (4): 469–78.  
  24. ^ Higgins, Guy A; Fletcher, Paul J (2003). "Serotonin and drug reward: Focus on 5-HT2C receptors". European Journal of Pharmacology 480 (1–3): 151–62.  
  25. ^ Kennett, G.A.; Clifton, P.G. (2010). "New approaches to the pharmacological treatment of obesity: Can they break through the efficacy barrier?". Pharmacology Biochemistry and Behavior 97 (1): 63–83.  
  26. ^ a b c Berg, Kelly A.; Harvey, John A.; Spampinato, Umberto; Clarke, William P. (2005). "Physiological relevance of constitutive activity of 5-HT2A and 5-HT2C receptors". Trends in Pharmacological Sciences 26 (12): 625–30.  
  27. ^ Berg, Kelly A.; Stout, Brian D.; Cropper, Jodie D.; Maayani, Saul; Clarke, William P. (1999). Receptor Systems"2C"Novel Actions of Inverse Agonists on 5-HT. Molecular Pharmacology 55 (5): 863–72.  
  28. ^ Reynolds, Gavin P.; Templeman, Lucy A.; Zhang, Zhi Jun (2005). "The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment". Progress in Neuro-Psychopharmacology and Biological Psychiatry 29 (6): 1021–8.  
  29. ^ Bray, Jenelle K.; Goddard, William A. (2008). "The structure of human serotonin 2c G-protein-coupled receptor bound to agonists and antagonists". Journal of Molecular Graphics and Modelling 27 (1): 66–81.  
  30. ^ a b Ahmed, Asif; Choo, Hyunah; Cho, Yong Seo; Park, Woo-Kyu; Pae, Ae Nim (2009). "Identification of novel serotonin 2C receptor ligands by sequential virtual screening". Bioorganic & Medicinal Chemistry 17 (13): 4559–68.  
  31. ^ Smith, B. M.; Smith, J. M.; Tsai, J. H.; Schultz, J. A.; Gilson, C. A.; Estrada, S. A.; Chen, R. R.; Park, D. M.; Prieto, E. B.; Gallardo, C. S.; Sengupta, D.; Thomsen, W. J.; Saldana, H. R.; Whelan, K. T.; Menzaghi, F.; Webb, R. R.; Beeley, N. R. A. (2005). "Discovery and SAR of new benzazepines as potent and selective 5-HT2C receptor agonists for the treatment of obesity". Bioorganic & Medicinal Chemistry Letters 15 (5): 1467–1470.  
  32. ^ Ahmad, S.; Ngu, K.; Miller, K. J.; Wu, G.; Hung, C. P.; Malmstrom, S.; Zhang, G.; o’Tanyi, E.; Keim, W. J.; Cullen, M. J.; Rohrbach, K. W.; Thomas, M.; Ung, T.; Qu, Q.; Gan, J.; Narayanan, R.; Pelleymounter, M. A.; Robl, J. A. (2010). "Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents". Bioorganic & Medicinal Chemistry Letters 20 (3): 1128.  
  33. ^ Conway, Richard J.; Valant, Celine; Christopoulos, Arthur; Robertson, Alan D.; Capuano, Ben; Crosby, Ian T. (2012). "Synthesis and SAR study of 4-arylpiperidines and 4-aryl-1,2,3,6-tetrahydropyridines as 5-HT2C agonists". Bioorganic & Medicinal Chemistry Letters 22 (7): 2560–4.  
  34. ^ Bray, George A.; Tartaglia, Louis A. (2000). "Medicinal strategies in the treatment of obesity". Nature 404 (6778): 672–7.  
  35. ^ Kimura, Yasuharu; Hatanakaa, Ken-ichi; Naitoua, Yuki; Maenob, Kyoichi; Shimadab, Itsuro; Koakutsua, Akiko; Wanibuchia, Fumikazu; Yamaguchia, Tokio (2004). "Pharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonist". European Journal of Pharmacology 483 (1): 37–43.  
  36. ^ Cryan, John F.; Lucki, Irwin (2000). Receptors"2C"Antidepressant-Like Behavioral Effects Mediated by 5-Hydroxytryptamine. The Journal of Pharmacology and Experimental Therapeutics 295 (3): 1120–6.  
  37. ^ Rosenzweig-Lipson, S.; Sabb, A.; Stack, G.; Mitchell, P.; Lucki, I.; Malberg, J. E.; Grauer, S.; Brennan, J.; Cryan, J. F.; Sukoff Rizzo, S. J.; Dunlop, J.; Barrett, J. E.; Marquis, K. L. (2007). "Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents". Psychopharmacology 192 (2): 159–170.  
  38. ^ a b Jensen, Nanna H.; Cremers, Thomas I.; Sotty, Florence (2010). "Therapeutic Potential of 5-HT2C Receptor Ligands". TheScientificWorldJOURNAL 10: 1870–85.  
  39. ^ Dunlop, J.; Watts, S. W.; Barrett, J. E.; Coupet, J.; Harrison, B.; Mazandarani, H.; Nawoschik, S.; Pangalos, M. N.; Ramamoorthy, S.; Schechter, L.; Smith, D.; Stack, G.; Zhang, J.; Zhang, G.; Rosenzweig-Lipson, S. (2011). "Characterization of Vabicaserin (SCA-136), a Selective 5-Hydroxytryptamine 2C Receptor Agonist". Journal of Pharmacology and Experimental Therapeutics 337 (3): 673–680.  
  40. ^ Tong, Z.; Chandrasekaran, A.; Demaio, W.; Jordan, R.; Li, H.; Moore, R.; Poola, N.; Burghart, P.; Hultin, T.; Scatina, J. (2009). "Species Differences in the Formation of Vabicaserin Carbamoyl Glucuronide". Drug Metabolism and Disposition 38 (4): 581–90.  
  41. ^ Bagdy, Gyorgy; Sved, Alan F.; Murphy, Dennis L.; Szemeredi, Katalin (1992). "Pharmacological characterization of serotonin receptor subtypes involved in vasopressin and plasma renin activity responses to serotonin agonists". European Journal of Pharmacology 210 (3): 285–9.  
  42. ^ Kahn, Rene S.; Wetzler, Scott (1991). "M-Chlorophenylpiperazine as a probe of serotonin function". Biological Psychiatry 30 (11): 1139–66.  
  43. ^ Kimura, Yasuharu; Naitou, Yuki; Wanibuchi, Fumikazu; Yamaguchi, Tokio (2008). "5-HT2C receptor activation is a common mechanism on proerectile effects of apomorphine, oxytocin and melanotan-II in rats". European Journal of Pharmacology 589 (1–3): 157–62.  
  44. ^ Hoyer, Daniel; Clarke, David E.; Fozard, John R.; Hartig, Paul R.; Martin, Graeme R.; Mylecharane, Ewan J.; Saxena, Pramod R.; Humphrey, Patrick P. A. (1994). "International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin)". Pharmacological Reviews 46 (2): 157–203.  
  45. ^ Kimura, Yasuharu; Naitou, Yuki; Wanibuchi, Fumikazu; Yamaguchi, Tokio (2006). "Characterization of Intracavernous Pressure Increase Induced by Ym348, a Novel 5-HT2C Receptor Agonist, in Anesthetized Rats". The Journal of Urology 175 (5): 1953–7.  
  46. ^ a b Andrews, M. D.; Fish, P. V.; Blagg, J.; Brabham, T. K.; Brennan, P. E.; Bridgeland, A.; Brown, A. D.; Bungay, P. J.; Conlon, K. M.; Edmunds, N. J.; Af Forselles, K.; Gibbons, C. P.; Green, M. P.; Hanton, G.; Holbrook, M.; Jessiman, A. S.; McIntosh, K.; McMurray, G.; Nichols, C. L.; Root, J. A.; Storer, R. I.; Sutton, M. R.; Ward, R. V.; Westbrook, D.; Whitlock, G. A. (2011). "Pyrimido\4,5-d]azepines as potent and selective 5-HT2C receptor agonists: Design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinence". Bioorganic & Medicinal Chemistry Letters 21 (9): 2715.  
  47. ^ Proximagen group plc. "Annual Report & Accounts 2011: Working together". Proximagen. Retrieved 26 September 2012. 
  48. ^ Pfizer. "Pfizer Pipeline". Pfizer. Retrieved 26 September 2012. 
  49. ^ FDA. "BELVIQ". Food and Drug Administration. Retrieved 26 September 2012. 
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.